Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02140177 · ClinicalTrials.gov registry record
Ask Suicide-Screening Questions to Everyone in Medical Settings (asQ em): Development of a Suicide Risk Screening Instrument for Adult Medical Inpatients
A clinical trial, sponsored by National Institute of Mental Health (NIMH).
- Completed
- Registry status
- 740
- Enrollment target
NCT02140177: Completed study, sponsored by National Institute of Mental Health (NIMH).
NCT02140177 is a clinical trial that has completed, run by National Institute of Mental Health (NIMH). The registered enrollment target is 740 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02140177 has completed, sponsored by National Institute of Mental Health (NIMH).
- COMPLETED
- Registry status
- 740 participants
- Enrollment target
Study Summary
Background: \- Suicide is the 10th leading cause of death for U.S. adults. Medically ill people are at an increased risk of suicide. Most people who have killed themselves went to a healthcare provider within 3 months of their death. More and more, hospitals are being asked to assess people for signs of suicide risk so that they can get the help they need. If nurses and doctors can find out who is at risk they can make sure these people get help in the hospital. The asQ em (Ask Suicide-Screening Questions to Everyone in Medical Settings) is a brief questionnaire. It was created to detect suicidal thoughts and behaviors in hospitalized people. Researchers would like to further develop this tool and figure out which are the best questions to ask patients. Objective: \- To determine the best questions for healthcare providers to ask people with medical illnesses to see if they are having suicidal thoughts or planning to hurt themselves. Eligibility: \- NIH Clinical Center patients over age 18. Design: * Participants will be asked questions about how they have been feeling in the past few weeks. They will be asked questions about depression, anxiety, and suicidal thoughts and behaviors. They also will be asked some background questions. * It will take approximately 15 to 30 minutes to answer the questions.
Primary Outcome
Short measures of suicide risk
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 740 participants |
| Start Date | 2014-05-14 |
| Est. Completion | 2020-02-28 |
What the finished NCT02140177 record still lists
NCT02140177 is an observational study that tracks outcomes without assigning an intervention. The registered 740 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT02140177 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02140177 about?
NCT02140177 is a clinical study titled "Ask Suicide-Screening Questions to Everyone in Medical Settings (asQ em): Development of a Suicide Risk Screening Instrument for Adult Medical Inpatients". Background: \- Suicide is the 10th leading cause of death for U.S. adults. Medically ill people are at an increased risk of suicide. Most people who have killed themselves went to a healthcare provider within 3 months of their death. More and more, hospitals are being asked to assess people for sig...
What is the current status of trial NCT02140177?
This trial is currently completed. The enrollment target is 740 participants. The study started on 2014-05-14. Estimated completion is 2020-02-28.
Who is sponsoring clinical trial NCT02140177?
This trial is sponsored by National Institute of Mental Health (NIMH), which has 343 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03963622 · 740 participants · NA
Careful Ventilation in Acute Respiratory Distress Syndrome (COVID-19 and Non-COVID-19)
- NCT04074135 · 740 participants · Phase 2
Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors
- NCT05215340 · 740 participants · Phase 3
Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
- NCT06172478 · 740 participants · Phase 2
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI